Emcure Pharmaceuticals Share Price

2,169.50192.91 (9.76%)

Live
As On: 04 Nov, 2026, 10:42 AM IST
As On: 04 Nov, 2026, 10:42 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	2,050.00
High	2,174.20
Low	2,035.10
Prev Close	1,976.60
Volume	8,02,935
VWAP(₹)	2,142.07

Share Price	Value
Today/Current/Last	2,169.502,160.00
Previous Day	1,976.601,982.55

Emcure Pharmaceutica Share Recommendations

Mean recosCurrent

BUY

9 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	5	5	5	5
Buy	3	3	3	1
Hold	1	1	1	1
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	9	9	9	7

View all Stock Recommendations

News & Analysis

Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 crore
News
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
News
MFs raise stake for 3 straight quarters in 5 mid-cap stocks; shares gain up to 75% YTD
News
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcements

View all Emcure Pharmaceutica Share News & Announcements

Financials

Income (P&L)

	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025
Total Income	2,823.73	2,582.52	2,473.70	2,365.33	2,272.95
Total Income Growth (%)	9.34	4.40	4.58	4.06	8.02
Total Expenses	2,342.30	2,157.46	2,086.12	2,013.56	1,898.99
Total Expenses Growth (%)	8.57	3.42	3.60	6.03	6.28
EBIT	481.43	425.06	387.58	351.77	373.96
EBIT Growth (%)	13.26	9.67	10.18	-5.93	17.78
Profit after Tax (PAT)	325.57	293.98	243.40	230.54	243.46
PAT Growth (%)	10.74	20.78	5.58	-5.31	17.64
EBIT Margin (%)	17.05	16.46	15.67	14.87	16.45
Net Profit Margin (%)	11.53	11.38	9.84	9.75	10.71
Basic EPS (₹)	17.16	15.50	12.84	12.16	12.85

	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025
Total Income	1,701.52	1,475.96	1,494.64	1,556.61	1,283.36
Total Income Growth (%)	15.28	-1.25	-3.98	21.29	14.78
Total Expenses	1,336.73	1,174.51	1,151.51	1,209.09	1,097.75
Total Expenses Growth (%)	13.81	2.00	-4.76	10.14	17.80
EBIT	364.80	301.45	343.13	347.52	185.61
EBIT Growth (%)	21.01	-12.15	-1.26	87.23	-0.32
Profit after Tax (PAT)	248.43	200.11	233.70	258.85	117.62
PAT Growth (%)	24.15	-14.37	-9.72	120.07	-4.21
EBIT Margin (%)	21.44	20.42	22.96	22.33	14.46
Net Profit Margin (%)	14.60	13.56	15.64	16.63	9.17
Basic EPS (₹)	13.10	10.55	12.33	13.65	6.21

	FY 2026	FY 2025	FY 2024	FY 2023
Total Revenue	9,216.20	7,963.26	6,715.24	6,031.72
Total Revenue Growth (%)	15.73	18.58	11.33	1.91
Total Expenses	7,897.71	6,981.53	5,978.08	5,278.36
Total Expenses Growth (%)	13.12	16.79	13.26	6.71
Profit after Tax (PAT)	924.36	681.33	498.18	532.02
PAT Growth (%)	35.67	36.76	-6.36	-19.66
Operating Profit Margin (%)	15.88	14.65	14.63	16.15
Net Profit Margin (%)	10.04	8.62	7.48	8.88
Basic EPS (₹)	48.77	36.43	27.54	29.42

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	5,452.70	4,500.73	3,635.91	3,232.44	3,519.92
Total Revenue Growth (%)	21.15	23.79	12.48	-8.17	7.79
Total Expenses	4,483.44	4,073.02	3,426.69	3,013.95	2,903.50
Total Expenses Growth (%)	10.08	18.86	13.69	3.80	7.94
Profit after Tax (PAT)	732.96	317.13	160.83	160.06	446.81
PAT Growth (%)	131.12	97.18	0.48	-64.18	6.26
Operating Profit Margin (%)	20.74	12.33	10.73	12.40	22.48
Net Profit Margin (%)	13.97	7.23	4.59	5.15	13.19
Basic EPS (₹)	38.67	16.95	8.89	8.85	24.71

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 1.56% of its operating revenues towards interest expenses and 16.87% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Total Assets	9,612.48	8,232.72	7,806.16	6,672.53
Total Assets Growth (%)	16.76	5.46	16.99	10.04
Total Liabilities	4,635.81	3,591.17	4,684.40	4,022.87
Total Liabilities Growth (%)	29.09	-23.34	16.44	1.86
Total Equity	4,976.67	4,641.55	3,121.77	2,649.66
Total Equity Growth (%)	7.22	48.68	17.82	25.33
Current Ratio (x)	1.43	1.71	1.33	1.27
Total Debt to Equity (x)	0.24	0.16	0.71	0.88
Contingent Liabilities	402.50	474.42	378.81	176.53

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	6,914.04	5,416.11	4,756.93	4,615.85	4,323.18
Total Assets Growth (%)	27.66	13.86	3.06	6.77	-11.10
Total Liabilities	3,203.45	2,391.75	2,821.83	2,773.98	2,610.65
Total Liabilities Growth (%)	33.94	-15.24	1.72	6.26	1.92
Total Equity	3,710.60	3,024.36	1,935.10	1,841.87	1,712.53
Total Equity Growth (%)	22.69	56.29	5.06	7.55	-25.60
Current Ratio (x)	1.34	1.43	1.00	1.07	1.10
Total Debt to Equity (x)	0.37	0.22	0.73	0.91	0.92
Contingent Liabilities	191.56	303.72	244.08	66.56	89.11

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Net Cash flow from Operating Activities	943.55	851.71	1,097.24	746.85
Net Cash used in Investing Activities	-1,193.06	-94.00	-712.51	-467.69
Net Cash flow from Financing Activities	343.43	-813.96	-164.21	-145.40
Net Cash Flow	112.08	-58.30	218.52	133.64
Closing Cash & Cash Equivalent	97.77	-14.31	43.99	-174.53
Closing Cash & Cash Equivalent Growth (%)	-783.15	-132.53	-125.21	-43.37
Total Debt/ CFO (x)	1.28	0.86	1.90	2.94

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	423.56	558.29	584.97	505.37	427.71
Net Cash used in Investing Activities	-948.10	-435.61	-171.08	-270.44	-189.00
Net Cash flow from Financing Activities	525.76	-49.25	-287.75	-54.52	-342.96
Net Cash Flow	2.51	71.38	124.15	180.30	-309.06
Closing Cash & Cash Equivalent	-15.02	-17.53	-88.91	-213.05	-393.35
Closing Cash & Cash Equivalent Growth (%)	-14.30	-80.29	-58.27	-45.84	366.68
Total Debt/ CFO (x)	3.23	1.17	2.42	3.30	3.68

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 1193.06 cr for investing activities which is an YoY increase of 1169.19%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Return on Equity (%)	18.67	15.32	16.87	21.27
Return on Capital Employed (%)	25.65	20.80	21.20	26.46
Return on Assets (%)	9.61	8.27	6.38	7.97
Interest Coverage Ratio (x)	13.07	8.77	5.43	5.74
Asset Turnover Ratio (x)	1.03	0.98	0.92	0.94
Price to Earnings (x)	32.79	29.85	-	-
Price to Book (x)	6.11	4.57	-	-
EV/EBITDA (x)	16.70	13.68	-	-
EBITDA Margin (%)	20.39	19.52	19.32	20.49

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	19.75	10.48	8.31	8.69	26.09
Return on Capital Employed (%)	23.40	14.62	14.28	14.70	31.87
Return on Assets (%)	10.60	5.85	3.38	3.46	10.33
Interest Coverage Ratio (x)	11.28	6.78	3.49	3.38	6.39
Asset Turnover Ratio (x)	0.85	0.86	0.75	0.70	0.74
Price to Earnings (x)	41.32	64.10	-	-	-
Price to Book (x)	8.15	6.72	-	-	-
EV/EBITDA (x)	23.69	27.39	-	-	-
EBITDA Margin (%)	25.44	17.47	16.58	18.14	27.37

Found Financials useful?

5 Days	14 Days	28 Days
80.64	66.86	62.11

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Emcure Pharmaceuticals Ltd.	37.01	8.13	18.67	25.65	9.61	15.02	15.88	10.22	48.77	1.43	0.24	1.28
Gland Pharma	45.94	5.01	9.91	13.96	8.21	20.18	23.67	15.97	62.35	4.68	0.02	0.24
Ipca Labs	38.21	5.25	14.15	17.23	9.22	15.36	17.98	12.35	46.94	2.76	0.09	0.62
Anthem Biosciences Ltd.	79.75	16.09	19.45	27.56	17.25	25.92	40.27	27.85	10.55	5.54	0.02	0.06
Ajanta Pharma	32.49	9.06	23.32	29.40	17.15	13.41	25.56	19.36	84.53	2.64	0.05	0.40
Add More

Annual Ratios (%)

Choose from Peers

Sai Life Science Ltd.
Piramal Pharma
Wockhardt
Rubicon Research Ltd.
Neuland Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Emcure Pharmaceuticals Ltd. Stock Performance	9.46	15.39	11.26	9.37	63.32	0.00	0.00
Gland Pharma Stock Performance	-0.34	3.26	9.53	21.88	64.68	108.43	-14.36
Ipca Labs Stock Performance	1.18	2.20	1.53	16.42	52.38	103.44	84.93
Anthem Biosciences Ltd. Stock Performance	1.19	3.90	1.03	5.54	23.12	0.00	0.00
Ajanta Pharma Stock Performance	-0.32	-4.35	-7.59	-6.12	26.76	81.25	126.84
Add More

Found Peer Comparison useful?

Category	No. of Shares	Percentage	% Change QoQ
Promoters	44,28,84,600	233.45 %	155.63
Pledge	1,80,000	0.12 %	0.07
FII	2,81,33,796	14.82 %	9.95
DII	4,83,20,280	25.47 %	17.02
MF	4,01,31,039	21.15 %	14.27
Others	4,97,93,265	-173.74 %	-182.59

Category	Sep 2026	Jun 2026	Mar 2026	Dec 2025
Promoters	233.45	77.83	77.87	77.87
Pledge	0.12	0.04	0.04	0.04
FII	14.82	4.87	3.35	3.59
DII	25.47	8.45	6.10	6.10
Mutual Funds	21.15	6.87	4.94	4.83
Others	-173.74	8.84	12.68	12.43

Mutual Funds Ownership

MF Ownership as on 30 September 2026

Kotak Mid Cap Direct-G
Equity: Mid Cap
3
- 838.40
  Amount Invested (in Cr.)
- 1.25861496%
  % of AUM
- 0.00
  % Change (MoM basis)
Nippon India Multi Cap Direct-G
Equity: Multi Cap
4
- 300.63
  Amount Invested (in Cr.)
- 0.56%
  % of AUM
- -5.06
  % Change (MoM basis)
Aditya Birla SL ELSS Tax Saver Direct-G
Equity: ELSS - Tax Saver
2
- 262.29
  Amount Invested (in Cr.)
- 1.93445942%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Board Meeting
Quarterly Results
Oct 14, 2026
General Meeting
-
Aug 31, 2026
Board Meeting
Quarterly Results
Jul 15, 2026

Board Meetings

Announced on	Meeting on
Oct 14, 2026	Nov 03, 2026
Quarterly Results
Jul 15, 2026	Aug 06, 2026
Quarterly Results
Apr 28, 2026	May 05, 2026
Audited Results & Final Dividend
Jan 22, 2026	Feb 04, 2026
Quarterly Results
Nov 03, 2025	Nov 11, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 05, 2026 Sep 04, 2026 36%
May 22, 2025 Aug 14, 2025 30%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Aug 31, 2026 Sep 21, 2026
-
Mar 24, 2026 Apr 28, 2026
-
Feb 18, 2026 Mar 24, 2026
-
Aug 04, 2025 Aug 28, 2025
-
Nov 25, 2024 Dec 25, 2024
-

Announced on	Ex-Date	Dividend%
May 05, 2026	Sep 04, 2026	36%
May 22, 2025	Aug 14, 2025	30%

Announced on	Meeting on
Aug 31, 2026	Sep 21, 2026
-
Mar 24, 2026	Apr 28, 2026
-
Feb 18, 2026	Mar 24, 2026
-
Aug 04, 2025	Aug 28, 2025
-
Nov 25, 2024	Dec 25, 2024
-

About Emcure Pharmaceutica

Emcure Pharmaceuticals Ltd., incorporated in the year 1981, is a Small Cap company (having a market cap of Rs 37,498.21 Crore) operating in Pharmaceuticals sector.

Emcure Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of Services for the year ending 31-Mar-2026.

For the quarter ended 30-06-2026, the company has reported a Consolidated Total Income of Rs 2,582.52 Crore, up 4.40 % from last quarter Total Income of Rs 2,473.70 Crore and up 22.73 % from last year same quarter Total Income of Rs 2,104.23 Crore. Company has reported net profit after tax of Rs 292.49 Crore in latest quarter.

The company’s top management includes Mr.Berjis Minoo Desai, Mr.Satish Ramanlal Mehta, Dr.Mukund Keshao Gurjar, Ms.Namita Vikas Thapar, Mr.Samit Satish Mehta, Mr.Sunil Rajanikant Mehta, Mr.C S Muralidharan, Dr.Shailesh Kripalu Ayyangar, Dr.Vidya Rajiv Yeravdekar, Mr.Vijay Keshav Gokhale, Mr.Tajuddin Sabir Shaikh, Ms.Amruta Yangalwar. Company has B S R & Co. LLP as its auditors. As on 30-09-2026, the company has a total of 18.97 Crore shares outstanding.

Emcure Pharmaceutica Share Price Today is Rs. 2169.50. On previous day, the Emcure Pharmaceutica Share Price (NSE) closed at Rs. 1883.5, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 30th Sep, 2026, the promoter held 77.82% of the stake in Emcure Pharmaceutica shares, out of which 0.04% was pledged. On the same date, foreign institutional investors' (FII) holdings of Emcure Pharmaceutica stocks was 14.82% as compared to 4.87% in Jun 2026 with increase of 9.95%. The domestic institutional investors (DII) holdings on 30th Sep, 2026 was 25.47% as compared to 8.45% in Jun 2026 with increase of 17.02%. Out of the total DII holdings in Emcure Pharmaceutica shares 21.15% was held by mutual funds. The rest including public held is -18.11%. Emcure Pharmaceutica stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Emcure Pharmaceutica Dividend: Ever since 1981, Emcure Pharmaceutica dividends has been paid out around 2 times. As on 04 Nov, 2026, 10:42 AM IST, The overall dividend yield for Emcure Pharmaceutica stands at 0.19%. The last dividend paid was on September 4, 2026 (Rs. 3.6). The Earnings Per Share (EPS) for quarter ending 30th Sep 2026 is Rs. 53.31.

Stock Forecast:
After showing 2823.72 Cr. of sales and 9.34% of quarterly net profit, there have been multiple ups and downs in the Emcure Pharmaceutica stock prices in the past few weeks. For example, Emcure Pharmaceutica stock price on 27th of October 2026 was around Rs. 1875.2. Emcure Pharmaceutica share price now stands at an average of Rs. 2169.50. Judging by last week's performance, stock is in up trend.

Emcure Pharmaceutica has a median target price of Rs. 2159.44 in 12 months by 9 analysts. They have provided a high estimate of Rs. 2330.0 and low estimate of Rs. 1900.0 for Emcure Pharmaceutica share.

Historical Prices and Performance:
Emcure Pharmaceutica, incorporated in 1981 is a Mid Cap company (with a market cap of Rs. 37498.21) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Emcure Pharmaceutica stock was 18.67%, 15.32%, 16.87%, 21.27% and 33.31% respectively.

Emcure Pharmaceutica announced 36.0% final dividend on September 4, 2026.

Key Metrics:
PE Ratio of Emcure Pharmaceutica is 35.33
Prices/Sales Ratio of Emcure Pharmaceutica is 3.29
Price/Book Ratio of Emcure Pharmaceutica is 7.18

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Emcure Pharmaceutica, major competitors and peers include Gland Pharma, Ipca Labs, Anthem Biosciences Ltd. and Ajanta Pharma. As of Jun 2026, the dividend yield of Emcure Pharmaceutica stands at 0.19% while Gland Pharma, Ipca Labs, Anthem Biosciences Ltd. and Ajanta Pharma stand at 0.0%, 0.31%, 0.0% and 0.84% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 35.33 and 7.18 respectively.

Leadership of Emcure Pharmaceutica :
Amruta Yangalwar is Co. Secretary & Compl. Officer
Tajuddin Sabir Shaikh is Chief Financial Officer
Berjis Minoo Desai is Chairman & Non-Exe.Director
Satish Ramanlal Mehta is Managing Director & CEO
Sunil Rajanikant Mehta is Whole Time Director
Namita Vikas Thapar is Whole Time Director
Samit Satish Mehta is Whole Time Director
Mukund Keshao Gurjar is Whole Time Director
Vidya Rajiv Yeravdekar is Independent Director
Shailesh Kripalu Ayyangar is Independent Director
Vijay Keshav Gokhale is Independent Director
C S Muralidharan is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

Nifty 500, BSE 500, BSE MidCap, BSE 250 SmallCap Index, BSE Healthcare

Address

Plot No. P-1 & P-2,IT-BT Park, Phase II,M.I.D.C., Hinjawadi,Pune, Maharashtra - 411057

Contact

investors@emcure.com

http://www.emcure.com

PE Ratio(x)	37.01
EPS - TTM(₹)	57.64
MCap(₹ Cr.)	40,302.13
MCap Rank	20
PB Ratio(x)	7.53
Div Yield(%)	0.17
Face Value(₹)	10.00
52W High(₹)	2,174.20
52W Low(₹)	1,306.50
MCap/Sales	3.29
Beta(1 Month)	-
BV/Share(₹)	262.33

PE Ratio(x)	37.43
EPS - TTM(₹)	57.64
MCap(₹ Cr.)	40,307.82
MCap Rank	20
PB Ratio(x)	7.56
Div Yield(%)	0.17
Face Value(₹)	10.00
52W High(₹)	2,180.80
52W Low(₹)	1,307.50
MCap/Sales	3.29
Beta(1 Month)	-
BV/Share(₹)	262.33

1 Day	9.76%
1 Month	11.57%
3 Months	9.68%
1 Year	63.77%
3 Years	N.A.
5 Years	N.A.

1 Day	8.95%
1 Month	11.13%
3 Months	9.25%
1 Year	62.97%
3 Years	N.A.
5 Years	N.A.

R1	2071.43	Pivot 1976.97	S1	1882.13
R2	2166.27		S2	1787.67
R3	2355.57		S3	1598.37

Emcure Pharmaceuticals Share Price

Key Metrics

Emcure Pharmaceutica share price insights

Emcure Pharmaceutica Share Price Returns

Emcure Pharmaceutica Share Recommendations

News & Analysis

Financials

Share Price Forecast

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Kotak Mid Cap Direct-G

Nippon India Multi Cap Direct-G

Aditya Birla SL ELSS Tax Saver Direct-G

Emcure Pharmaceutica Top Searches

Corporate Actions

About Emcure Pharmaceutica

Executive Leadership

Auditors

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News